Achieve Life Sciences, Inc. (ACHV) Stock Analysis & Investment Frameworks
Achieve Life Sciences, Inc. (ACHV) stock analysis on Invetso. Review Achieve Life Sciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Achieve Life Sciences, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Achieve Life Sciences, Inc. Key Financial Metrics
- Market Cap: $667.83M
- Revenue: $N/A
- ROE: -892.07%
- ROIC: -21425.74%
- Dividend Yield: N/A
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.